Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations (Q59650414)

From Wikidata

Jump to navigation Jump to search

scholarly article by Garret A FitzGerald published March 2002 in American Journal of Cardiology

Language	Label	Description	Also known as
English	Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations	scholarly article by Garret A FitzGerald published March 2002 in American Journal of Cardiology

Statements

scholarly article

0 references

Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations (English)

0 references

1 reference

based on heuristic

inferred from title

author name string

Garret A FitzGerald

1

0 references

language of work or name

0 references

publication date

March 2002

0 references

American Journal of Cardiology

0 references

89

0 references

6

0 references

26-32

0 references

Cyclooxygenases 1 and 2

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Genetic and pharmacological analysis of prostanoid receptor function

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Prostaglandin and thromboxane biosynthesis

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Cyclooxygenase-2 and its regulation in inflammation

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis.

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs.

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Cyclooxygenase-1 and Cyclooxygenase-2 Selectivity of Widely Used Nonsteroidal Anti-Inflammatory Drugs

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

The coxibs, selective inhibitors of cyclooxygenase-2.

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear str

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Platelet activation in unstable coronary disease

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Increased Prostacyclin Biosynthesis in Patients with Severe Atherosclerosis and Platelet Activation

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Acetylation of prostaglandin synthase by aspirin

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Aspirin as an antiplatelet drug

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Platelet-active drugs : the relationships among dose, effectiveness, and side effects

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Altered pain perception and inflammatory response in mice lacking prostacyclin receptor

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Cyclooxygenase-2 blockade does not impair endothelial vasodilator function in healthy volunteers: randomized evaluation of rofecoxib versus naproxen on endothelium-dependent vasodilatation

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Lipid peroxidation and platelet activation in murine atherosclerosis

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Cardiovascular responses to the isoprostanes iPF(2alpha)-III and iPE(2)-III are mediated via the thromboxane A(2) receptor in vivo

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Risk of cardiovascular events associated with selective COX-2 inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Cyclooxygenase inhibitors and the antiplatelet effects of aspirin

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries

1 reference

https://api.crossref.org/works/10.1016/S0002-9149(02)02234-8

7 January 2021

Identifiers

10.1016/S0002-9149(02)02234-8

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q59650414&oldid=1543127691"